Kyle Kolaja PhD

Kyle Kolaja is currently the Vice President of Business Development at Cellular Dynamics International (CDI), a leading developer of stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. Prior to joining CDI, Dr. Kolaja was Leader/Global Head of Predictive Toxicology Screens and Investigative Toxicology-US at Roche, where he oversaw laboratories that conduct all safety screening assays, provided toxicology support to projects, and applied stem cell-derived tissues to safety. Prior to joining Roche, Dr. Kolaja was Vice President of Chemogenomics and Toxicology at Iconix Pharmaceuticals, and prior to that, he was a project toxicologist and site head of investigative toxicology at Searle/Pharmacia. Dr. Kolaja has served as President of the Society of Toxicology's Drug Discovery Toxicology Specialty Section, is currently President-elect of the Stem Cells and Toxicology Specialty Sections, and is on the board of directors for the American Board of Toxicology. Dr. Kolaja has nearly 60 peer-reviewed publications and reviews (including seven to eight in the last year on applications of stem cell-derived tissues in early safety). He received his B.S. degree from Michigan State University and his Ph.D. degree in toxicology from Indiana University (mentor, James Klaunig) and conducted his postdoctoral research at the University of Kansas (mentor, Curt Klaassen).